文献速递核素与放射性配体治疗肿瘤 PET/CT

亲和体介导PNA预靶向联合曲妥珠单抗改善HER2表达移植瘤小鼠生存

Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts.
PubMed 文献 · J Nucl Med · 2021-10-28

该研究在HER2表达的SKOV-3移植瘤小鼠中比较了曲妥珠单抗单药、亲和体-PNA预靶向放射治疗及两者联合的疗效。结果显示联合治疗组全部小鼠存活且7只肿瘤消失,疗效优于单药,且未观察到明显毒性。

要点

  • 亲和体与曲妥珠单抗结合HER2不同表位,体外互不干扰。
  • 联合治疗组10只小鼠全部存活,7只肿瘤消失。
  • 联合治疗未引起体重下降或肝肾病理改变。

核心结论

  • 曲妥珠单抗与亲和体介导PNA预靶向放射治疗联合可显著延长HER2表达移植瘤小鼠生存,且对正常组织无毒。

研究设计与样本

  • 实验治疗研究,使用HER2表达的SKOV-3移植瘤小鼠,设溶剂对照、曲妥珠单抗单药、预靶向单药和联合治疗组,伦理许可限制观察至90天。

主要发现

  • 曲妥珠单抗组中位生存75.5天,显著长于溶剂对照组的59.5天。
  • 预靶向单药组至90天未达中位生存,10只中6只存活,2只完全缓解。
  • 联合治疗组10只全部存活,7只肿瘤消失。
  • 各组动物体重无显著差异,肝肾未检出显著病理改变。

关键数值与推荐

  • 体外实验显示大摩尔过量曲妥珠单抗不影响ZHER2:342-SR-HP1对HER2表达细胞的亲和力,反之亦然。

临床怎么用

  • 提示HER2靶向抗体与亲和体预靶向放射治疗联合可能作为HER2表达肿瘤的潜在治疗策略。

局限性

  • 研究仅在小鼠移植瘤模型中进行,伦理许可限制观察至90天。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of patients with human epidermal growth factor receptor 2 (HER2)-expressing tumors using the monoclonal antibody trastuzumab increases survival. The Affibody-based peptide nucleic acid (PNA)-mediated pretargeted radionuclide therapy has demonstrated efficacy against HER2-expressing xenografts in mice. Structural studies suggest that Affibody molecules and trastuzumab bind to different epitopes on HER2. The aim of this study was to test the hypothesis that a combination of PNA-mediated pretargeted radionuclide therapy and trastuzumab treatment of HER2-expressing xenografts can extend survival compared with monotherapies. Methods: Mutual interference of the primary pretargeting probe ZHER2:342-SR-HP1 and trastuzumab in binding to HER2-expressing cell lines was investigated in vitro. Experimental therapy evaluated the survival of mice bearing HER2-expressing SKOV-3 xenografts after treatment with vehicle, trastuzumab only, pretargeting using Affibody-PNA chimera ZHER2:342-SR-HP1 and complementary probe 177Lu-HP2, and combination of trastuzumab and pretargeting. The ethical permit limited the study to 90 d. The animals' weights were monitored during the study. After study termination, samples of liver and kidneys were evaluated by a veterinary pathologist for toxicity signs. Results: The presence of a large molar excess of trastuzumab had no influence on the affinity of ZHER2:342-SR-HP1 binding to HER2-expressing cells in vitro. The affinity of trastuzumab was not affected by a large excess of ZHER2:342-SR-HP1 The median survival of mice treated with trastuzumab (75.5 d) was significantly longer than the survival of mice treated with a vehicle (59.5 d). Median survival of mice treated with pretargeting was not reached by day 90. Six mice of 10 in this group survived, and 2 had complete remission. All mice in the combination treatment group survived, and tumors in 7 mice had disappeared at study termination. There was no significant difference between animal weights in the different treatment groups. No significant pathologic alterations were detected in livers and kidneys of treated animals. Conclusion: Treatment of mice bearing HER2-expressing xenografts with the combination of trastuzumab and Affibody-mediated PNA-based radionuclide pretargeting significantly increased survival compared with monotherapies. Cotreatment was not toxic for normal tissues.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Oroujeni M, Tano H, Vorobyeva A, et al. Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts. J Nucl Med. 2021. PMID: 34711617. doi:10.2967/jnumed.121.262123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。